Chen Chen

发表

Correction: High Weight Loss during Radiation Treatment Changes the Prognosis in Under-/Normal Weight Nasopharyngeal Carcinoma Patients for the Worse: A Retrospective Analysis of 2433 Cases

Yun-Fei Xia, Lujun Shen, Chen Chen, 2013, PLoS ONE.

A CT‐based radiomics model to predict subsequent brain metastasis in patients with ALK‐rearranged non–small cell lung cancer undergoing crizotinib treatment

Li Zhang, Haifeng Li, Yongluo Jiang, 2022, Thoracic cancer.

Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy

Hui Chang, Shiliang Liu, Yuan-hong Gao, 2020, BMC Cancer.

The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis

Hui Chang, Yun-Fei Xia, Y. Xia, 2019, Cancer Cell International.

Anti‐epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first‐line treatment for recurrent or metastatic nasopharyngeal carcinoma

Li Zhang, Sha Fu, W. Fang, 2020, Cancer medicine.

Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer

Shaodong Hong, L. Luo, Chen Chen, 2022, Journal of Cancer Research and Clinical Oncology.

Necessity of concurrent chemotherapy in N2‐3 nasopharyngeal carcinoma treated with neoadjuvant chemotherapy of ≥3 cycles followed by intensity‐modulated radiotherapy

Yong-hong Hu, Hui Chang, Yuan-hong Gao, 2019, Cancer medicine.

PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma

Sha Fu, Shaodong Hong, Chen Chen, 2022, Frontiers in Immunology.

Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus

Li Zhang, Haifeng Li, Shaodong Hong, 2021, Cancer Immunology, Immunotherapy.

Pretreatment platelet count as a predictor for survival and distant metastasis in nasopharyngeal carcinoma patients

Yun-Fei Xia, Lujun Shen, Yupei Chen, 2015, Oncology letters.

Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer

Ping Chen, Hui Yu, Xiuyu Cai, 2021, Cancer Immunology, Immunotherapy.

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy

Li Zhang, Shaodong Hong, Hongyun Zhao, 2019, Journal of Immunotherapy for Cancer.

Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum

Li Zhang, Sha Fu, Shaodong Hong, 2020, Cancer management and research.

Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy

Yue Chen, F. Passiglia, I. Oh, 2021, Translational Lung Cancer Research.

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis

Y. Huang, X. Hou, Li Zhang, 2018, Journal of Immunotherapy for Cancer.

Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy

Y. Huang, Li Zhang, Haifeng Li, 2021, Frontiers in Oncology.

Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy.

Li Zhang, Haifeng Li, Yongluo Jiang, 2021, Lung cancer.

Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapy.

W. Du, Li Zhang, Haifeng Li, 2021, Lung cancer.

Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition

R. Xu, Li Zhang, Xiuyu Cai, 2019, Journal of Immunotherapy for Cancer.

Unsatisfied Reporting Quality of Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy in Cancer

Li Zhang, Yongluo Jiang, Chen Chen, 2021, Frontiers in Immunology.

Surrogate endpoints shortening the therapeutic evaluation duration for different subgroups of patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: A retrospective analysis of 830 patients stratified by the 8th edition of the UICC/AJCC staging system and plasma Epstein-B

Hui Chang, Yun-Fei Xia, Wen-Wen Zhang, 2018, Journal of Cancer.

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer

Hui Yu, Sha Fu, Bei Zhang, 2021, Journal for ImmunoTherapy of Cancer.

Serum Apolipoprotein A-I Predicts Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy

Hui Chang, Yuan-hong Gao, Chen Chen, 2021, Cancer management and research.

Optimize the dose of oxaliplatin for locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy followed by radical surgery and adjuvant chemotherapy

Hui Chang, Shiliang Liu, Yuan-hong Gao, 2020, BMC Cancer.

First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.

Li Zhang, Haifeng Li, Sha Fu, 2019, Lung cancer.

The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis

Hui Chang, Yun-Fei Xia, Guan-nan Wang, 2019, Cancer Cell International.

Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma

Hui Chang, Yun-Fei Xia, Wen-Wen Zhang, 2019, Medicine.

Machine learning-based risk model incorporating tumor immune and stromal contexture predicts cancer prognosis and immunotherapy efficacy

Haifeng Li, Yongluo Jiang, Sha Fu, 2023, iScience.

Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials

Yun-Fei Xia, S. Zheng, Chen Chen, 2021, Journal of Cancer Research and Therapeutics.

Placebo immune-related adverse events (irAEs): A neglected phenomenon in cancer immunotherapy trials

Chen Chen, Yixin Zhou, Xuanye Zhang, 2024, European Journal of Cancer.